NASDAQ:PBM Psyence Biomedical (PBM) Stock Price, News & Analysis $4.01 -0.17 (-4.07%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.01 0.00 (0.00%) As of 08/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Psyence Biomedical Stock (NASDAQ:PBM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Psyence Biomedical alerts:Sign Up Key Stats Today's Range$3.95▼$4.1650-Day Range$2.36▼$11.5052-Week Range$2.36▼$341.34Volume182,334 shsAverage Volume4.98 million shsMarket Capitalization$2.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. Read More Psyence Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScorePBM MarketRank™: Psyence Biomedical scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Psyence Biomedical. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPsyence Biomedical has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.81% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently decreased by 37.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPsyence Biomedical does not currently pay a dividend.Dividend GrowthPsyence Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.81% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently decreased by 37.98%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News SentimentN/A News SentimentPsyence Biomedical has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Psyence Biomedical this week, compared to 1 article on an average week.Search Interest7 people have searched for PBM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Psyence Biomedical to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Psyence Biomedical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Psyence Biomedical is held by insiders.Percentage Held by Institutions77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Psyence Biomedical's insider trading history. Receive PBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psyence Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address PBM Stock News HeadlinesPsyence Biomedical Ltd. (PBM) Stock Price Today - WSJAugust 5, 2025 | wsj.comPsyence Biomedical stock soars after partner achieves ibogaine breakthroughAugust 1, 2025 | za.investing.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Psyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction BreakthroughAugust 1, 2025 | msn.comPsyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31, 2025 | financialpost.comFPsyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31, 2025 | globenewswire.comPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesJune 25, 2025 | globenewswire.comPsyence Biomedical regains Nasdaq compliance after reverse splitJune 18, 2025 | investing.comSee More Headlines PBM Stock Analysis - Frequently Asked Questions How have PBM shares performed this year? Psyence Biomedical's stock was trading at $16.8167 at the start of the year. Since then, PBM shares have decreased by 76.2% and is now trading at $4.01. How were Psyence Biomedical's earnings last quarter? Psyence Biomedical Ltd. (NASDAQ:PBM) announced its quarterly earnings results on Thursday, January, 23rd. The company reported $4.06 EPS for the quarter. When did Psyence Biomedical's stock split? Shares of Psyence Biomedical reverse split before market open on Monday, May 5th 2025.A 100-797 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Psyence Biomedical's major shareholders? Top institutional investors of Psyence Biomedical include Parallel Advisors LLC (48.25%). How do I buy shares of Psyence Biomedical? Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Psyence Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), Saba Capital Income & Opportunities Fund (BRW), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ). Company Calendar Last Earnings1/23/2025Today8/08/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBM Previous SymbolNASDAQ:PBM CIK1985062 Webwww.psyencebiomed.com Phone510-214-3750FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.04 Quick Ratio11.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$1.75 per share Price / Cash Flow2.29 Book Value$11.83 per share Price / Book0.34Miscellaneous Outstanding Shares570,000Free Float548,000Market Cap$2.29 million OptionableN/A Beta0.22 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PBM) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.